Resibufogenin Anti-Cancer Mechanisms: BRAF and MAPK Pathway Targets

Experimental and computational data from a study exploring the anti-tumor effects of resibufogenin (RBG) on castration-resistant prostate cancer (CRPC). The dataset includes results from cell viability assays, network pharmacology analysis, and molecular docking simulations. It was authored by Yuanxin Xing and last updated on April 14, 2026.

Use Cases

• Validate predicted drug-target interactions based on molecular docking results for BRAF and SRC.
• Analyze the role of the MAPK signaling pathway in prostate cancer treatment based on KEGG analysis results.
• Correlate in vitro anti-proliferative effects with intracellular ROS levels from the experimental data.
• Identify potential drug candidates by comparing the inhibitory effects of 20 ROS-related compounds on PC3 cells.

Strengths

• Data is derived from multiple validation methods, including in vitro experiments, network pharmacology, and molecular dynamics simulation.
• The dataset is licensed under CC-BY-4.0, allowing for open sharing and reuse.
• The study design includes a comparative analysis of 20 ROS-related compounds.

Limitations

• The dataset is very small at 25.4 KB, indicating limited scope.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.

Provenance

Source

figshare, authored by Yuanxin Xing.

Collection Method

Data generated from in vitro experiments (CCK-8, colony formation, ROS detection, Western blot) and computational analyses (network pharmacology, molecular docking, molecular dynamics simulation).

Freshness

Last updated 2026-04-14 04:14:29; freshness should be verified.